ArticleMicrobiology spectrum2025
Granuloma and persistent detection of wild-type rubella virus in an immunocompromised patient.
Article in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Rubella-associated granuloma in a patient with a compound heterozygous RAG1 defect and review of the literature.Immunologic research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report a case of wild-type rubella virus (genotype 2B) granuloma in a 29-year-old immunocompromised patient with a full vaccination scheme. He had been followed since his early teens for an unlabeled systemic inflammatory disease. On an inguinal node biopsy, histological analysis revealed a nguudiffuse non-necrotic granulomatous inflammation with no identified conventional infectious agent involved in granuloma formation. Further virological investigation revealed rubella virus (RuV) RNA detected by reverse transcription polymerase chain reaction (RT-PCR). Wild-type viral RNA persistence was documented in plasma samples collected up to 25 months after initial detection and also in different sequential biological samples (cerebrospinal fluid and nasopharyngeal swab). In the context of incomplete rubella eradication, RuV must be added to the list of potential triggers of chronic granuloma in immunodeficient patients.IMPORTANCERubella has become rare but has not yet disappeared. Rubella virus (RuV) must be added to the list of potential triggers of granuloma, particularly in immunodeficient patients. Diagnosis of RuV granulomas requires molecular testing of biopsy. RuV sequencing distinguishes between wild-type and vaccine-derived viruses and enables epidemiological surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.